By the end of 2024, the company had more than 80 projects for drugs under development (calculated by indications), including innovator drugs, biosimilars. In 2024, the company applied for 220 patents in the pharmaceutical manufacturing segment, including 3 US patents and 18 PCT applications, with 66 patents granted.